Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 VENUS REMEDIES   MYLAN
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-23
MYLAN
Dec-18
VENUS REMEDIES/
MYLAN
5-Yr Chart
Click to enlarge
High Rs3793,967-   
Low Rs1452,184-   
Sales per share (Unadj.) Rs415.51,825.4-  
Earnings per share (Unadj.) Rs19.949.6-  
Cash flow per share (Unadj.) Rs44.0391.3-  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %00-  
Book value per share (Unadj.) Rs344.31,974.7-  
Shares outstanding (eoy) m13.37514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x0.61.7 37.4%   
Avg P/E ratio x13.262.0 21.2%  
P/CF ratio (eoy) x5.97.9 75.7%  
Price / Book Value ratio x0.81.6 48.8%  
Dividend payout %00-   
Avg Mkt Cap Rs m3,5011,582,214 0.2%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m5700-   
Avg. sales/employee Rs Th026,833.1-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0728.6-  
INCOME DATA
Net Sales Rs m5,555939,158 0.6%  
Other income Rs m1030-   
Total revenues Rs m5,658939,158 0.6%   
Gross profit Rs m602243,019 0.2%  
Depreciation Rs m323175,847 0.2%   
Interest Rs m345,170 0.0%   
Profit before tax Rs m37922,002 1.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m114-3,500 -3.2%   
Profit after tax Rs m26625,502 1.0%  
Gross profit margin %10.825.9 41.9%  
Effective tax rate %30.0-15.9 -188.3%   
Net profit margin %4.82.7 176.1%  
BALANCE SHEET DATA
Current assets Rs m3,230524,425 0.6%   
Current liabilities Rs m826382,364 0.2%   
Net working cap to sales %43.315.1 286.1%  
Current ratio x3.91.4 285.2%  
Inventory Days Days3784 44.2%  
Debtors Days Days50493 539.8%  
Net fixed assets Rs m2,781182,181 1.5%   
Share capital Rs m134500 26.7%   
"Free" reserves Rs m4,4700-   
Net worth Rs m4,6031,015,998 0.5%   
Long term debt Rs m3871,096,588 0.0%   
Total assets Rs m6,0112,725,301 0.2%  
Interest coverage x130.01.5 8,743.1%   
Debt to equity ratio x0.11.1 7.8%  
Sales to assets ratio x0.90.3 268.2%   
Return on assets %4.52.6 172.3%  
Return on equity %5.82.5 229.9%  
Return on capital %7.73.2 240.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m00-   
CASH FLOW
From Operations Rs m366195,157 0.2%  
From Investments Rs m-508-100,875 0.5%  
From Financial Activity Rs m-6-90,916 0.0%  
Net Cashflow Rs m-2201,617 -13.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 83.34 Rs / USD

Compare VENUS REMEDIES With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare VENUS REMEDIES With: ALPA LAB  MARKSANS PHARMA.  GENNEX LAB.  WALPAR NUTRITIONS LTD.  BLUE JET HEALTHCARE  



Today's Market

Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising(Closing)

After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.